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Abstract (250 words) 
 
Background: Antibody Fc-driven engagement of macrophages is critical for evoking cellular activation and 
effector functions and influencing tumour-associated macrophage (TAM) recruitment. We previously reported 
that IgE class antibodies promote restriction of cancer growth in rodent models associated with significant TAM 
infiltration. However, the human macrophage-associated IgE-Fc Receptor (FceR) axis remains unexplored. We 
investigated the effects of anti-tumour IgE stimulation on human macrophage activation.  
Methods: Human blood monocyte-differentiated quiescent (M0), classically-(M1) and alternatively-(M2) 
activated macrophages were crosslinked with IgE and polyclonal antibodies to mimic immune complex formation. 
We examined surface marker expression, cytokine secretion, protein kinase phosphorylation and gene expression 
in IgE-stimulated macrophages and IgE antibody-dependent macrophage-mediated cytotoxicity (ADCC) against 
tumour cells. 
Findings: A proportion (40%) of M2 and (<20%) M0 and M1 macrophages expressed the high-affinity IgE 
receptor FcεRI. IgE crosslinking triggered upregulation of co-stimulatory CD80, increased TNFα, IFNγ, IL-1β, 
IL-12, IL-10, IL-13, CXCL9, CXCL11 and RANTES secretion by M0 and M2 and additionally enhanced MCP-
1 by M2 macrophages. IgE-stimulated M1 macrophages retained secretion of pro-inflammatory cytokines. IgE 
crosslinking enhanced the FceRI-dependent signalling pathway, including phosphorylation of the Lyn kinase, 
ERK1/2 and p38 in M2 macrophages and upregulated Lyn gene expression by M1 and M2 macrophages. Anti-
tumour IgE engendered ADCC of cancer cells by all macrophage subsets. 
Interpretation: IgE can engage and re-educate alternatively-activated macrophages towards pro-inflammatory 
phenotypes and prime all subsets to mediate anti-tumour functions. This points to IgE-mediated cascades with 
potential to activate immune stroma and may be significant in the clinical development of strategies targeting 
tumour-resident macrophages. 
  
Introduction 
Tumour-associated macrophages (TAMs) form a significant proportion of the immune cell infiltrate and are 
thought to play important roles in defining the pro- or anti-tumour status of the tumour microenvironment (TME). 
The mechanisms by which macrophages can influence tumorigenesis, though, has been controversial: these cells 
represent a multi-faceted immune compartment and their contributions in shaping a pro- or anti-tumour 
environment heavily depend on their polarisation status (1). While the conventional binary model of macrophage 
polarisation of classically-activated (M1) and alternatively-activated M2 subsets may be imprecise, generally 
tumour-associated macrophage infiltrates are thought to favour an alternatively-activated M2-like phenotype. 
TAMs, featuring M2 characteristics, have been demonstrated to permit or promote tumour growth and their 
presence in the tumour tissue has been associated with poor prognosis in some solid tumours of various origins, 
such as melanoma, head and neck, lung, colorectal and breast cancers (2). For these reasons, TAMs are now 
considered a potential target for cancer immunotherapy (3–6). 
Several anti-cancer approaches targeting macrophages have been explored aiming to either inhibit their tumour-
supporting functions or to promote their anti-tumour effects. More specifically, macrophage-centred anti-cancer 
strategies can include macrophage depletion, modification of macrophage recruitment and macrophage re-
polarization or re-programming. Macrophage reprogramming involves the suppression of alternatively-activated 
(M2) macrophages or, possibly, the stimulation of an M1-biased phenotype in the TME (7). The development of a 
monoclonal antibody targeting the pattern recognition scavenger MARCO (8) is the first antibody therapeutic 
approach designed to re-programme TAMs.  
The demonstration that re-polarisation of macrophages can be achieved through monoclonal antibody treatment 
opened the door to the development of new therapeutics targeting macrophage surface proteins (specifically those 
involved in maintaining an M2-like phenotype). We previously demonstrated that treatment with MOv18 IgE, a 
monoclonal human/chimeric antibody engineered with Fc regions of the IgE class and specific for a tumour-
associated antigen (TAA) (Folate Receptor alpha, FRα), triggered an immune-activatory TNFα/MCP-1 axis in 
tumours, which resulted in recruitment of macrophages into tumour lesions and was associated with significantly-
reduced tumour growth (9), in a syngeneic immunocompetent lung metastases rat model. These findings suggested 
that IgE antibodies may activate and recruit macrophages towards tumours and thus may represent a treatment 
approach capable of engaging these cells against cancer (3,10). However, while activation of mast cells and 
subsequent release of pro-inflammatory mediators have been largely described (11,12), very little is known regarding 
IgE-Fcε Receptor interactions and their downstream effects on macrophage activation and functions, especially 
with regards to distinct macrophage subpopulations (13). 
In our study we investigated how a monoclonal antibody (SF-25 IgE) targeting a TAA, can engage and activate 
human macrophages of different activation states. We investigated human macrophage expression of IgE 
receptors, the potential effects of IgE crosslinking on surface marker expression, soluble mediator release, 
phosphorylation and gene expression of kinases known to be associated with FceR signalling. Furthermore, we 
investigated whether macrophages of different polarisation states can trigger effector functions against cancer 
cells by anti-tumour IgE, with the aim of ascertaining the potential of antibodies of the IgE class to promote 
macrophage-mediated anti-tumour activity.  
Materials and Methods 
 
Isolation of human peripheral blood mononuclear cells (PBMC) 
K2EDTA-spray coated collection tubes were used to collect peripheral venous blood (50 ml) from healthy donors. 
To isolate PBMCs, equal volumes of blood and 2% FCS/2 mM EDTA were gently mixed to a final volume of 30 
ml and gently pipetted on top of 15 ml of Ficoll-PaqueTM PLUS density gradient in a 50 ml conical tube. The tube 
was then centrifuged at 1200 x g with slow acceleration and no brake at room temperature (RT) for 20 minutes. 
The plasma interface was collected and washed with PBS at 600 x g at 4°C for 10 minutes. The erythrocytes 
present in the sample were lysed with RBC lysis buffer for 5 minutes at RT, followed by washing with PBS + 2% 
FCS/2 mM EDTA. Human samples were collected with informed written consent, in accordance with the Helsinki 
Declaration. Study design was approved by the Guy’s Research Ethics Committee, Guy’s and St. Thomas’ NHS 
Foundation Trust. Peripheral blood was also obtained through the UK National Health System (NHS) Blood and 
Transplant system from anonymous donor leukocyte cones. 
 
Isolation of human monocytes from peripheral blood 
Isolated PBMCs were passed through a 40 µm cell strainer to remove cell clumps. Next, PBMCs were transferred 
in a new vial and washed with PBS at 600 x g for 5 minutes. After discarding the supernatant, cells were 
resuspended in 400 µl of MACS buffer (PBS + 0.5% FCS/2 mM EDTA). Human monocytes were isolate by 
negative selection, following the Pan Monocyte Isolation Kit protocol (Miltenyi Biotec). The purity of monocytes 
was evaluated by flow cytometry staining with a BV786-conjugated monoclonal antibody anti-CD14 and BV711-
conjugated anti-CD16. Acquisitions were performed using a BD FACS Canto™ II at the Biomedical Research 
Centre Flow Cytometry Core, King’s College London.  
 
Differentiation of human macrophages ex vivo from peripheral blood monocytes 
Isolated monocytes were resuspended in RPMI 1640 2% FBS to promote adhesion and cells were seeded in 6-
well plates at a density of 1-1.5 x106 cells/ml; each well was loaded with 2 ml of cell suspension and plates were 
placed in a tissue culture incubator. After 2 hours of incubation, medium was carefully removed. Each well was 
washed with 1 ml of warm sterile PBS and replenished with 2 ml of RPMI 1640 supplemented with 10% FCS 
and penicillin/streptomycin with the addition of 20 ng/ml of M-CSF (Monocyte Colony Stimulating Factor) to 
allow monocyte to grow ex vivo. Thereafter, every 3 days, half of the volume in each well fresh were replaced 
with media containing 25 ng/ml GM-CSF (for M1) or 40 ng/ml M-CSF (for M2). On Day 7, 20 ng/ml of 
Interferon-Gamma (IFNγ) and 100 ng/ml of Lipopolysaccharide (LPS) were added to GM-CSF cells for 72 hours. 
M-CSF cells were instead added with 20 ng/ml of Interleukin-4 (IL-4) for 72 hours. 
 
Flow cytometric assessment of antibody binding to antigen and cell surface receptors 
Binding of SF-25 IgE and IgG1 to FcεR- and FcγR-expressing cells or antigen-expressing cells was evaluated by 
using 105 cells per sample. Cells were detached with PBS+5 mM EDTA, resuspended in PBS+2% FBS (FACS 
buffer) and incubated with 5 µg/ml of primary antibody for 30 minutes at 4°C, followed by a wash with 3 ml of 
FACS buffer (spinning at 500g for 5 minutes). Cells were incubated with the secondary antibody goat anti-human 
IgE–fluorescein isothiocyanate (FI-3040; Vector Laboratories) or goat anti-human IgG1–fluorescein 
isothiocyanate (FI-3080; Vector Laboratories) at 30 µg/ml in FACS buffer for 30 minutes at 4°C, followed by one 
wash as above. Samples were resuspended in 100 µl of FACS buffer and analysed with a BD FACS Canto™ II. 
 
Detection on endogenous IgE on differentiated macrophages 
M0, M1 and M2 monocyte-derived (MDM) macrophages were detached with Accutase and 1x105 cells were 
aliquoted in FACS tubes in RPMI1640 medium supplemented with 2% FBS. Cells were incubated with 5 µg/ml 
of IgE antibody for 30 mins at 4°C. Macrophages were then washed with PBS to remove any unbound antibody. 
Cells were then treated with 1 µg/ml of goat polyclonal anti-human IgE–fluorescein isothiocyanate (FI-3040; 
Vector Laboratories) for 30 additional mins at 4°C. Cells were washed again with PBS by centrifugation for 5 
mins at 400xg and resuspended in FACS buffer, before analysing them on a BD FACS Canto™ II. 
 
IgE crosslinking on human macrophages 
M0, M1 and M2 (MDM) macrophages were incubated with 5 µg/ml of IgE antibody for 30 mins at 37°C by 
adding the antibody solution directly onto the cell culture plate. Cells wells were washed with PBS to remove any 
unbound antibody. Cells were then treated with 1 µg/ml of goat polyclonal anti-human IgE–fluorescein 
isothiocyanate (FI-3040; Vector Laboratories) for 30 more mins at 37°C. Cells were harvested 4 hours after 
stimulation to examine soluble mediator release and 24 h after stimulation to investigate surface marker 
expression. 
 
Magnetic Luminex Assay of macrophage supernatants for cytokine detection 
Macrophage supernatants were collected 4 hours post-stimulation, centrifuged at 600 x g to remove floating cells 
and diluted 1:1 with sterile PBS. The multiplex assay was performed with the Magnetic Luminex Kit following 
the protocol instructions. The plate was sealed and left on the shaker up to 90 minutes until ready to be analysed 
on a LuminexTM analyzer. 
 
Flow cytometry assessment of surface protein expression on macrophages  
The day after the treatments, cells were detached with Accutase (Sigma). Plates were incubated for 10 minutes at 
37°C to facilitate detachment. After the incubation, 1 ml of RPMI 1640 supplemented with 10% FCS and 
penicillin/streptomycin was added to each well. Cells were counted, washed with PBS by centrifugation at 400 x 
g for 5 minutes and resuspended at a concentration of 1x106 cells/ml. 5 ml poly-propylene tubes were used for 
staining and flow cytometry acquisition. To each sample, 1 µl of each of the staining antibody solution was added, 
and cells were incubated for staining at 4°C for 40 minutes, before being washed with 2 ml of FACS buffer and 
centrifuged as above. Cells were resuspended in 100 µl of PBS only and stained for live/dead cell discrimination 
with LIVE/DEAD® Fixable Dead Cell Stain Near-IR and incubated at room temperature for 30 minutes in the 
dark. Tubes were added with 2 ml of PBS and washed by centrifugation as above, before being resuspended in 
200 µl of FACS buffer and acquired at BD FACS Canto™ II. 
 
Investigation of gene expression via Real Time Quantitative PCR (RT-qPCR)  
cDNA samples were diluted 1:4 with RNAse/DNAse free water and 2 µl were distributed in triplicate on a fast-
optical 96-well reaction plate. A qPCR master mix was prepared by mixing 10 µl of TaqMan gene expression 
master mix, 1 µl of GAPDH Probe, 1 µl of the GOI Probe (T cell (or transmembrane) immunoglobulin and mucin 
domain protein 3 Tim-3 or Lyn kinase) and 6 µl RNAse free water. The qPCR master mix was added to every well 
containing DNA. Negative qPCR controls included cDNA-free wells. 40 cycles of RT-qPCR were performed. 
 
Cytotoxicity/Phagocytosis (ADCC/ADCP) Assay to study IgE antibody functions in activating 
macrophages against cancer cells 
ADCC/ADCP assays were performed using a protocol adjusted from a previously-described method (14). Briefly, 
target tumour cells were labelled with Carboxyfluorescein succinimidyl ester (CFSE) the day before performing 
the assay. For this, cells were detached with trypsin and washed once in RPMI 1640 complete medium. Cells were 
then resuspended in 100 µl PBS, and 0.75 µl of 0.5 mM CSFE was added for every 1x106 cells. Cells were 
incubated at 37°C for 10 minutes and the reaction was stopped with one wash in ice-cold RPMI 1640 standard 
medium. Normal culture conditions were resumed overnight. The following day, CFSE-labelled tumour cells were 
detached using PBS + 5mM EDTA, washed in RPMI 1640 standard medium and re-suspended to 1x105 cells/100 
µl culture medium. Macrophages were detached with Accutase (Sigma), re-suspended in culture medium and 
mixed with the tumour cells at a 10:1 ratio. Cells were placed in FACS tubes and co-incubated at 37°C for 3 hours 
in the presence of either PBS or 5 µg/ml of either SF-25 IgE or control antibody. After incubation, cells were 
washed in FACS buffer and macrophages were identified by staining mixed cell populations with 5 µg/ml of anti-
human CD206-APC/Cy7-conjugated antibody to detect M1 or anti-human CD163-PE/Cy7-conjugated for M2 for 
30 minutes at 4°C. Cells were washed once and re-suspended in 200 µl FACS buffer for immediate acquisition 
using a dual laser FACSCantoTM (Becton Dickinson). Every sample was treated with 100 µl of DAPI (100 ng/ml), 
mixed using a vortex and acquired immediately. Tumour cell killing was calculated on the percentage of DAPI+ 
tumour cells and the total number of tumour cells in SF-25 antibody-treated samples compared to negative 
controls. Analysis of flow cytometry data was performed by FlowJo (TreeStar Inc) software. 
 
Analysis of the Phosphorylation profile of kinases 
Proteome Profiler Human Phospho-Kinase Array (R&D Systems) were incubated with 400 µg lysate overnight at 
4°C. The following day, chemiluminescent detection was performed according to manufacturer’s indications. 
Densitometry analysis was conducted using ImageJ. 
 
Study of FcεRI pathway in macrophages 
Pathway analysis was performed using the Reactome Pathway Analysis tool (15).The set of genes of 
phosphorylated kinases used for input was the combined superset from those perturbed under both IgE stimulation 
of M1 and M2. In order to determine the ability of each gene product to discriminate between the observed 
differences in M1 and M2 phosphorylation, the difference in fold change between M1 and M2 was calculated. 
The M1/M2 difference in fold change was used to weight each gene when inferring implicated pathways. Kinases 
were considered “perturbed” by IgE-crosslinking when the t-test p-value performed on the means of each 
condition (baseline/IgE crosslinked), resulted in a P value of <0.05. A False Discovery Rate of less than 0.05 and 
a minimum gene set size of 4 was used to filter the results. Overly general pathways and processes were manually 
removed. Version 67 of the Reactome database was used. The KEGG database was used to depict the structure of 
the FcεRI pathway.  
 Statistical methods and analyses of publicly-available databases 
All statistical analyses were performed using GraphPadTM Prism Software (version 6.0). Error bars represent SD 
and SEM in in vitro and in ex vivo evaluations. Clinical associations of gene expression were assessed using 
publicly-available data in Kaplan-Meier Plotter (http:/kmplot.com/analysis/). One way-ANOVA was performed 
in combination with Bonferroni’s or Tukey’s post-test to determine statistical significance of the data. 
  
Results 
 
Human monocyte-derived macrophages express typical M1 and M2 differentiation surface markers and 
express IgE Fc receptors 
To evaluate the impact of Fc engagement of IgE on human macrophage populations, we firstly confirmed the 
characteristics of classically-activated (M1) and alternatively-activated (M2) subsets (2). Human primary 
monocytes isolated from peripheral blood by negative selection and magnetic bead purification (16,17) comprised 
the three classical (CD14++, CD16-), intermediate (CD14+, CD16+) and alternative (CD14-, CD16++) subsets 
(Supplementary Figure 1A). Non-adherent, non-monocytic cells were removed after two hours of seeding in 
serum-free medium, consistently yielding > 80% monocyte purity based on CD14 and CD16 expression and 
physical parameters (Supplementary Figure 1A-B). Macrophages were differentiated over 7 days (Figure 1A), 
followed by cytokine stimulation (IFNγ+LPS for M1, IL-4 for M2) for 72 hours, to obtain classically (M1) and 
alternatively (M2) activated macrophage subsets, respectively. Consistent with previous reports (18), differentiated 
populations showed the expected morphology profiles: fried egg-shape like GM-CSF and M1 macrophages, and 
fibroblast-like, needle-shaped M-CSF macrophages, which further elongated after treatment with IL-4 (Figure 
1A). 
We ascertained expression of key markers of macrophage differentiation (co-stimulatory molecules CD80, CD86 
for M1; the scavenger receptor cysteine-rich family member CD163 (or M130), and the mannose receptor CD206 
for M2) (Figure 1B). Consistent with previous studies, peripheral blood monocytes expressed CD86 but not CD80 
(19). A high proportion of M1 macrophages expressed both CD80 and CD86. We found expression of CD163 (20) 
on 50% of freshly isolated monocytes and on a high proportion of alternatively-activated (M2) macrophages. 
Furthermore, 10% of primary monocytes and the majority of M1 and M2 macrophages expressed CD206, in line 
with previous reports (21). These findings confirmed the differentiation of classically- and alternatively-activated 
macrophage subsets from human monocytes.  
Very little information is available regarding IgE receptor expression for distinct macrophage subpopulations (13). 
We found that 20% of peripheral blood monocytes expressed the high affinity IgE Fc receptor FcεRI, while 1-2% 
expressed the low affinity receptor FcεRII (CD23), in line with previously published studies (22,23) (Figure 1C). 
M2 macrophages displayed the highest levels of cell surface expression of FceRI (40% of cells, n=4), while CD23 
expression was expressed by 15-20% of all macrophage phenotypes (M0, M1, M2).  
Based on the high affinity of IgE for cognate Fc receptors and its slow dissociation rates most notably following 
binding to FceRI on immune cells, we hypothesised that some endogenous IgE may be retained by effector cells 
ex vivo in the absence of antigen engagement and immune complex formation (24,25). An anti-human IgE FITC-
conjugated antibody was used to detect endogenous IgE and also following treatment with anti-tumour IgE (SF-
25) to understand whether free IgE Fcε receptors were available for exogenous IgE to bind and, to crosslink these 
on the surface of macrophages (26–28). Over 20% of M0 macrophages were detected to still have cell surface-bound 
endogenous IgE when incubated with anti-IgE antibody alone (Supplementary Figure 2). Both M1 and M2 
macrophages showed detectable but lower endogenous IgEs on their surface. All cell subsets could also bind 
exogenous IgEs.  
Together, as previously demonstrated with primary human monocytes (29,30), these findings indicate that IgE Fc 
receptors were not saturated on the surface of human macrophages and that exogenous IgEs could still engage 
with these cognate Fcε receptors despite the presence of endogenously-bound IgE. 
 
IgE crosslinking on macrophages upregulates M1 surface marker CD80 levels and triggers secretion of a 
distinct cytokine chemokine signature by M0 and M2 macrophages  
We previously reported that systemic administration of rat anti-tumour IgE was associated with recruitment of 
CD80+ macrophages into syngeneic tumours of immunocompetent rats (9). Here we investigated whether IgE 
stimulation might impact on human classically and alternatively activated macrophage surface marker expression. 
Human macrophage subsets were incubated with either anti-tumour (SF-25) IgE or the hapten-specific antibody 
NIP IgE. IgE-Fcε receptor crosslinking was triggered by polyclonal anti-human IgE. Crosslinking of IgE on 
macrophages did not affect CD14, FceRI or CD23 surface expression, while FcgRIII (CD16) expression by M2 
macrophages was reduced with crosslinking of both SF-25 and NIP IgE (Supplementary Figure 2). Surface 
expression of CD80 was upregulated on M0 and M2 macrophages when cell bound IgE was crosslinked but 
remained unaltered on M1 macrophages. Neither IgE engagement nor crosslinking affected CD163 or CD206 
surface expression on any of the cell subsets. 
Based on previous evidence that IgE can influence macrophage recruitment and activation in rodent models (9), 
we investigated whether IgE crosslinking of Fce receptors on the surface of different human macrophage subsets 
could influence soluble mediator release (Figure 2A): 
Pro-inflammatory cytokines TNFα, IFNγ, IL-12, IL-1β: Crosslinking of IgE led to a drastic increase (from 100 to 
approximately 2,000 pg/ml) in TNFa secretion in both M0 and M2 macrophages, while IgE did not affect the low 
TNFa levels produced by M1 cells (Figure 2B). IgE crosslinking enhanced IFNg secretion by both M0 and M2 
subsets. M1 macrophages showed a 4-fold higher baseline levels of IFNg compared to the other subsets and these 
remained stable upon activation via IgE. Furthermore, M0 and M2 macrophages increased IL-12 production from 
100 to approximately 1500-2000 pg/ml when crosslinked with IgE/anti-IgE. M1 cells featured a greater baseline 
level of IL-12 (ca. 1,500 pg/ml), which remained unaffected upon IgE treatment. Baseline concentration of IL-1β 
were very low in all three cell subsets. Crosslinking of cell-bound IgE triggered increased IL-1β secretion in M0 
and M2 macrophages, while stimulation did not influence production by M1 macrophages.  
Anti-inflammatory cytokines IL-4, IL-6, IL-10, IL-13: IL-4 production slightly increased upon IgE crosslinking 
in both M0 and M2 subsets and remained unaffected in M1 cells. Baseline levels of IL-10 and IL-13 were similar 
between macrophage subsets, however IgE crosslinking upregulated IL-10 and IL-13 release by M0 and M2 
subsets but not by M1 macrophages. IL-6 secretion remained unchanged in M1 macrophages but increased upon 
treatment with IgE only and with IgE/anti-IgE crosslinking in both M0 and M2 subsets (Figure 2C). 
Interferon Gamma-induced chemokines MIG (CXCL9) and I-TAC (CXCL11): In M1 macrophages, secretion of 
MIG (CXCL9) and I-TAC (CXCL11) remained unchanged (ca. 400 pg/ml) with IgE stimulation, while 
crosslinking of IgE in M0 and M2 macrophages led to modest increases. Levels of I-TAC (CXCL11) were 4-fold 
greater in M1 macrophages (ca. 400 pg/ml) compared to M0 and M2 at baseline, however, IgE crosslinking 
increased secretion of I-TAC (CXCL11) by M0 and M2 cultures from ca. 80 to ca. 160 pg/ml in M0 cells and 
from 50 to ca. 200 pg/ml in M2 macrophages (Figure 2D). 
Macrophage chemoattractant chemokines MCP-1 (CCL2) and RANTES (CCL5): In a rat model of cancer and in 
human monocytes in vitro, Josephs and colleagues demonstrated, that IgE crosslinking triggered a TNFα/MCP-1 
axis, which resulted in recruitment of macrophages into tumours (9). Here, crosslinking of cell-bound IgE produced 
no modulation of MCP-1 supernatant concentration in either M0 or M1 macrophages. However, M2 macrophages, 
responded to IgE activation by enhancing the release of MCP-1. M0 and M2 but not M1 macrophages increased 
production of RANTES with IgE crosslinking, with the peak concentrations following IgE stimulation 
corresponding approximately to the baseline concentration in M1 cells (Figure 2E). 
Together these data demonstrate that crosslinking of cell-bound IgE triggered enhanced expression of cytokines 
TNFa, IFNg, IL-12, IL-1b, IL-6, IL-10, IL-13 and of the chemokines MIG (CXCL9), I-TAC (CXCL11) and 
RANTES (CCL5) by M2 and M0 macrophages. IgE crosslinking on M2 macrophages but not on M0 or M1 
subsets, triggered enhanced secretion of the chemoattractant MCP-1 (CCL2). On the other hand, M1 macrophages 
appeared to retain their cytokine/chemokine expression upon IgE activation including expression of pro-
inflammatory mediators such as IFNg and IL-12 (Table 1). 
 
Crosslinking of IgE on M1 and M2 macrophages regulates phosphorylation levels of protein kinases 
downstream of FceRI signalling pathway 
Crosslinking of differentiated macrophages M1 and M2 with IgE/anti-IgE resulted in modification of the 
phosphorylation levels of intracellular kinases, analysed via a phosphorylation array (Figure 3A). Amongst 43 
kinases analysed, overall 29 were significantly perturbed in IgE-stimulated macrophages. M2 macrophages were 
characterised by a marked increase in phosphorylation levels compared to the M1 subset, which in contrast 
displayed a decrease of phosphorylation for the majority of kinases analysed (Figure 3B). M2 macrophages 
displayed a marked increase (1.25-5-fold changes) in the phosphorylation of HSP27, p38, p27, ERK1/2 and Lck 
kinases following crosslinking. Crosslinking of IgE on M1 macrophages induced downregulation of p38, ERK1/2, 
STAT5a/b, GSK3a/b, Chk2 and FAK phosphorylation, while some kinases showed upregulated phosphorylation 
of maximum 0.2-fold change compared to baseline (Figure 3C). MSK1/2 was the only kinase displaying slightly 
increased phosphorylation of 0.2-fold change in both macrophage subsets (Figure 3C). 
In order to investigate whether IgE stimulation influenced FceRI signalling, commonly known to be activated on 
mast cells, we interrogated the publicly-available KEGG database to depict the FceRI signalling pathway. 
Molecular species whose phosphorylation level was measured ex vivo from IgE-stimulated differentiated human 
macrophages are depicted in blue (Figure 4A). Since the FceRI signalling pathway in human macrophages is 
relatively unexplored, we interrogated a publicly available database (Reactome) with the proteome phospho-
profiler dataset to dissect differences between M1 and M2 macrophage signalling cascades upon IgE crosslinking. 
IgE crosslinking on macrophages triggered phosphorylation of kinases known in mast cells to be found 
downstream of the FcεRI pathway network (generated via the KEGG database) (Figure 4A). Furthermore, a 
number of signalling pathways appeared to be differentially activated following IgE crosslinking in the two 
macrophage subsets (VEGFA-VEGFR2 pathway, PI3K/AKT and Rho GTPases signalling amongst others), with 
the MAPK family pathway being the most differentiating between classically- and alternatively-activated 
macrophages (Figure 4B). These findings confirm for the first time that IgE stimulation potentiates activation of 
kinases downstream of the FceRI signalling pathway in macrophages and reflect differential intracellular 
mechanisms specific for each alternatively-activated and classically-macrophage subset triggered by activation of 
FceRI. 
 
IgE crosslinking on macrophages modulates gene expression of Lyn and Tim-3 and Lyn gene expression is 
associated with a favourable prognosis in solid tumours 
We next investigated the gene expression of the protein kinase Lyn and the checkpoint molecule Tim-3 (T cell or 
transmembrane immunoglobulin and mucin domain protein 3), both known to participate in the FceRI signalling 
pathway in mast cells (31). Upon IgE crosslinking, Lyn mRNA expression increased to 2-, 7- and 70-fold in M0, 
M1 and M2 macrophages, respectively (Figure 5A, left). M2 macrophages downregulated Tim-3 expression upon 
IgE activation, while M0 macrophages increased Tim-3 gene expression by 150-fold in response to IgE 
crosslinking compared to untreated cells (Figure 5A, right). Together these data demonstrate that the FceRI 
pathway can be activated with IgE on macrophage subsets ex vivo and gene expression of Lyn and Tim-3 are 
differentially regulated by IgE on distinct macrophage subsets. 
To gain insights into a potential clinical relevance of IgE/FcεR signalling through Lyn and Tim-3, we interrogated 
publicly-available gene expression datasets for solid tumours of different origins (Figure 5B). We found 
significant association of improved 5-year overall survival with elevated expression of Lyn in gastric (P=7.7e-08), 
lung (P=6.7e-05) and ovarian (P=0.036) cancers. These findings suggest that enhanced Lyn gene expression - one 
of the downstream signalling effects of IgE crosslinking its FceR on alternatively-activated and classically-
activated macrophages - may be associated with better prognosis in cancer patients. On the other hand, the 
association of Tim-3 gene expression with clinical outcomes appeared dependent on the tumour type: specifically, 
higher levels of Tim-3 expression in lung and ovarian cancers correlated with improved patient prognosis, while 
it was associated with less favourable overall survival in patients with gastric cancer. This suggests that Tim-3 
may exert different functions in different malignancies. These findings may be significant in future IgE class-
mediated immune cell activation in different solid tumour types.  
 
M0, M1 and M2 derived human macrophages can be activated by anti-tumour IgE to kill cancer cells 
We assessed whether human macrophages derived ex vivo can be activated by IgE to kill cancer cells by applying 
a three-colour flow cytometric assay to detect cytotoxicity and phagocytosis (14) (Figure 6A). The anti-tumour 
antibody SF-25 IgE was successful in engaging all three macrophage subsets, M0, M1 and M2 to mediate tumour 
antigen-specific ADCC of A-2058 cancer cells compared with non-specific antibody-treated or no antibody 
control cells (Figure 6B). SF-25 IgE triggered approximately 30% of tumour cell-killing above controls. On the 
other hand, treatment of macrophages and A-2058 tumour cells with SF-25 IgG1 isotype antibody did not produce 
effective tumour cell killing above isotype controls. These findings support the notion that IgE antibodies can 
activate human macrophages to kill tumour cells ex vivo, but also that both M1 and M2 subsets can engage with 
antibodies of the e class and target cancer cells by exerting antigen-specific cytotoxic activity. 
In summary, crosslinking IgE antibodies on the surface of human macrophages influenced their polarisation status 
(Figure 7), leading quiescent macrophages to acquire M1-like features, M1 macrophages to retain their pro-
inflammatory status and skewing differentiated M2 macrophages towards a pro-inflammatory phenotype, with 
measurable anti-tumour activity when tumour antigen-specific IgE could target macrophages against cancer cells.  
Discussion 
 
Macrophages represent a major component of the tumour microenvironment in many solid cancers. Their 
phenotypes and activation states can be influenced in the TME in response to environmental stimuli, so that 
different macrophage subsets could orchestrate different and often opposite aspects of the immune response, 
striking a balance between anti-tumour immunity and wound healing or inflammation. The potential of antibodies 
to influence the dynamics and polarisation states of these cells against cancer may offer opportunities to tip the 
balance in favour of host immunity. However, the mechanisms of human macrophage-associated immune 
complex formation engendered by different antibody isotypes, and especially through the IgE/FceR (IgE FcR) 
axis, remain insufficiently understood.  
We have previously reported that systemic treatment with anti-tumour IgE reduced tumour growth in different in 
vivo models of cancer, associated with significant recruitment of macrophages towards tumours (9,29). However, 
the mechanisms by which therapeutic antibodies of the IgE class can engage, influence and activate tissue 
macrophage populations, especially those likely to form part of the tumour microenvironment, remain unexplored. 
In this study we investigated whether IgE stimulation may influence the polarisation and activation states of 
classically- and alternatively-activated macrophage populations. For this purpose, we derived human 
macrophages displaying the typical markers of M1 (classically-activated) or M2 (alternatively-activated) 
phenotypes and cytokine profiles (32). We therefore explored the presence of cognate Fce receptors on the surface 
of classically- and alternatively-activated macrophages and interrogated the effect of IgE engagement and of 
crosslinking of macrophage-bound IgE on each subset.  
Around 40% of M2 macrophages expressed the high affinity IgE receptor FcεRI, while approximately 20% of 
cells in each subset expressed the low affinity IgE receptor CD23. Macrophage cell surface-bound IgE crosslinked 
on alternatively-activated macrophages triggered increased expression of the co-stimulatory molecule CD80, a 
typical M1 macrophage marker. Upregulation of the co-stimulatory molecule CD80 on the surface of professional 
antigen-presenting cells (APC) including macrophages, may signify cell maturation and also confer capacity for 
effective antigen presentation and may point to the potential of IgE class antibodies to promote macrophage 
maturation, polarisation and APC functions. These findings are consistent with previously described evidence of: 
a) infiltration of immune cells, including macrophages, in human ovarian cancer patient-derived xenograft 
residual tumours in immunocompromised mice treated with an anti-tumour IgE and human PBMCs as effector 
cells; and b) higher recruitment of monocyte/macrophages into tumours and enhanced expression of CD80+ rat 
macrophages into syngeneic tumours in an immunocompetent rat model following systemic treatment with rat 
MOv18 IgE (4,9). Furthermore, in our study, IgE stimulation did not interfere with the expression of CD163 on 
either macrophage population. In concordance, we previously reported that in rats treated with anti-tumour IgE, 
tumour-infiltrating rat macrophages did not upregulate the M2 marker CD163 (9). Together, these indicate that 
activation of the IgE/FcεR pathway may influence macrophage phenotype and maturation. 
We furthermore explored whether IgE stimulation may promote differential activation of specific macrophage 
subsets. In M1 macrophages, IgE crosslinking retained the production of key pro-inflammatory cytokines 
including IFNγ and IL-12. In concordance, in Josephs et al, we recently demonstrated upregulation of pro-
inflammatory immune-associated pathways including IL-12 and NK-cell immune activation signatures in the 
lungs of tumour-bearing rats treated with MOv18 IgE (10). Considering these findings, it is possible that IgE 
engagement and crosslinking may at least retain M1 macrophages in a manner consistent with their known pro-
inflammatory and antigen-presenting functions. 
Importantly, secretion of IL-1β, IL-6, IL-10, IL-12, IL-13, IFNγ, RANTES, MIG and I-TAC was triggered by 
crosslinking of cell-bound IgE on quiescent M0 and on M2 macrophages. This may suggest that the two subsets 
might feature similar molecular mechanisms in their ability to regulate activation of the FcεRI pathway. 
Furthermore, production of all soluble mediators tested was either retained at the same level or increased with 
IgE-crosslinking. Although the cytokine panel secreted by M0 and M2 after crosslinking with IgE did not 
correspond to a defined macrophage subtype, the mediator signature displayed by IgE-stimulated cells may 
represent a newly polarised macrophage subset secreting both pro- and anti-inflammatory mediators, as well as 
chemoattractant factors (Table 1). An additional result that also points at the development of a macrophage state 
with activatory features is increased release of CXCL9 with IgE stimulation in M0 and M2 macrophages: CXCL9 
represents an important anti-angiogenic factor, known to be predominantly expressed by the M1 phenotype (33). 
Since CXCL9 is a direct counter-regulatory mediator of VEGF signalling known to influence macrophage 
polarisation (34), future studies may also directly assess the impact of IgE antibody stimulation on the expression 
of VEGF by different macrophage subsets. 
We also report that IgE crosslinking on both M0 and M2 macrophages triggered enhanced levels of the pro-
inflammatory M1 cytokine TNFα, which this had different effects in M0 and M2 macrophages in the relation to 
the production of the macrophage chemoattractant MCP-1. M2 macrophages, upon IgE treatment, enhanced the 
production and the release of MCP-1. In line with the findings presented in this work, upregulation and the 
potential roles of TNFα and MCP-1 have been described by Josephs and colleagues. Our previous findings with 
the anti-tumour IgE antibody MOv18 in a rat tumour model in vivo suggested that tumour antigen-specific IgE 
treatment influences the spatial distribution and activation of macrophages around tumour lesions. Systemic IgE 
treatment in this model was also associated with a specific cytokine signature, featuring elevated levels of TNFα, 
MCP-1 and IL-10 in the tumour microenvironment and upregulated expression of TNFα by tumour-associated 
macrophages in rat lungs. Furthermore, ex vivo crosslinking of MOv18 IgE, triggered TNFα upregulation by 
human monocytes. TNFα stimulation triggered production of MCP-1 by macrophages and also by tumour cells 
of different origins. MCP-1 triggered monocyte and macrophage infiltration in the tumour microenvironment. 
These studies demonstrated the significance of the TNFα/MCP-1 axis in the modulation of cellular populations 
and functions in the TME (9,35). Our findings that M0 and M2 macrophages can be stimulated to secrete TNFα and 
that alternatively activated M2 macrophages are the only cell type that upregulated MCP-1 upon crosslinking by 
IgE, suggest that IgE has the capacity to specifically stimulate this normally anti-inflammatory subset to a more 
mature, further activated phenotype, which bears some characteristics normally associated with the classically-
activated M1 macrophages. Further investigation of the effects of IgE antibodies on the expression of additional 
soluble mediators such as IL-17A, and other family members, and IL-37, reported to influence macrophage 
phenotype, may shed light into the impact of IgE-FcεRs interactions in the tumour microenvironment (36,37).  
Analysis of gene expression of the protein kinase Lyn and Tim-3 both part of the FcεRI signalling pathway and 
known to regulate effector cell activation (38), showed that crosslinking of IgE on macrophages upregulated Lyn 
gene expression in M0, M1 and M2 macrophage subtypes. This may be significant in the cancer context since in 
vivo studies demonstrated that a loss-of-function of Lyn may predispose to tumorigenesis (39), and transgenic 
mouse models lacking Lyn were characterised by defective macrophage populations (40). The retention and 
upregulation of Lyn expression on all macrophage subsets may therefore signify the importance of activating 
macrophages by antibodies of the IgE isotype, which could potentially confer protection from tumour growth. 
The potential of activating the FcεR downstream pathway, and by inference anti-tumour IgE engagement of 
immune effector cells may have clinical significance, since higher intra-tumoural Lyn expression in gastric, lung 
and ovarian cancer is associated with more favourable prognosis. On the other hand, engagement and crosslinking 
of IgE induced a reduction in Tim-3 gene expression in M2 macrophages, while Tim-3 was upregulated in M0 
macrophages. Tim-3, known to participate in multiple suppressor pathways of anti-tumour responses, can be 
expressed by cancer cells and may support alternatively-activated macrophage polarisation. Simultaneous 
blocking of Tim-3 and PD-1 in infectious diseases was shown to restore lymphocyte functions and it was recently 
hypothesised that blocking Tim-3 may support the anti-tumour functions by macrophages (41). IgE crosslinking 
and subsequent reduction in Tim-3 gene expression in M2 macrophages may induce immune cell activation, in 
line with what was observed with T lymphocytes upon treatment with anti-PD-1 and anti-Tim-3 antibodies. 
Therefore, reduction of Tim-3 expression on M2 macrophages upon IgE treatment may be further explored in the 
context of cancer immunotherapy and macrophage functions in the TME.  
In summary, analysing surface marker expression, soluble mediator release, gene expression and protein 
phosphorylation on human macrophages derived ex vivo upon IgE crosslinking may provide a new insight on this 
antibody class that may have relevance in tissues and perhaps in TME. Quiescent M0 macrophages, when 
crosslinked with IgE, featured: upregulation of the classic M1 surface marker CD80, increased production of pro-
inflammatory cytokines and chemoattractant mediators, increased expression of the kinase Lyn and other 
downstream signalling molecules including Erk1/2 and p38. M1 macrophages retained their pro-inflammatory 
status upon activation via IgE antibodies, which led to increased expression of Lyn downstream of the FcεRI 
pathway. The crosslinking of IgE antibodies on M2 macrophages was characterised by a significant increase in 
the production of the chemoattractant, pro-inflammatory molecule MCP-1 and the enhanced phosphorylation and 
gene expression of Lyn. Therefore, crosslinking of IgE on human macrophages confers M0 and M2 subsets 
features more likely associated with classically-activated macrophages (Figure 7), leading to polarised 
macrophage phenotypes. Our functional assays indicate that anti-tumour IgE antibodies can engage human 
macrophages to elicit an effector function response against cancer cells. We show for the first time that IgE can 
activate macrophages of different polarisation states to kill cancer cells. This supports the notion that tissue type 
macrophages, including those subsets commonly associated with tumour lesions, could be engaged and re-
educated by anti-tumour IgE antibodies, and importantly, that IgE could unleash their cytotoxic potential against 
target tumour cells.  
The anti-cancer potential of IgE class antibodies has been reported in multiple studies in the emerging field of 
AllergoOncology, concerned with the links between Th2 and IgE responses with cancer (42,43). Reports include an 
IgE antibody recognising the cell surface tumour antigen HER2/neu which restricted tumour growth in human 
FcεRI transgenic mice. Furthermore, Fazekas-Singer et al. reported the development of a canine IgE targeting the 
epidermal growth factor receptor (EGFR) shown to engage and activate canine macrophages more effectively 
than the equivalent IgG1 to target and kill tumour cells in vitro (44). Human adipose tissue-derived mast cells 
(ADMC) can be specifically activated to display tumoricidal activity against breast cancer cells when engaged 
with tumour antigen-specific IgEs (45). Our own studies have demonstrated the capacity of an anti-FRα IgE 
antibody (MOv18) to restrict tumour growth in several model systems and to recruit monocytes and macrophages 
against tumours, supporting the progress of this agent to a first-in-class Phase I clinical trial in oncology 
(NCT02546921, www.clinicaltrials.gov).  
Taken together, our findings point to the potential of anti-tumour IgE antibodies not only to mediate immune 
effector cell-mediated killing of cancer cells, but also to impact on immune stroma, influencing macrophage 
phenotype and maturation states. Our findings provide new insights into the interactions between human 
macrophages and IgE class antibodies. This may be highly significant in the clinical development of new 
immunotherapy strategies targeting these often tissue- and tumour-resident cells and may point to previously-
unappreciated cascades with potential to activate and re-educate immune stroma. 
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Figure Legends 
Figure 1. M1 and M2 macrophages are obtained through ex vivo differentiation of human monocytes 
(a) Flowchart depicting the isolation and cell culture methodology to derive M1 and M2 macrophages ex vivo. (b) 
Flow cytometric analysis of M1 and M2-typical surface markers CD80, CD86, CD163, CD206 representing the 
percentage of positive cells to anti-human CD80-BV395, anti-human CD86-BV737, anti-human CD163-BV605, 
anti-human CD206-PE/Cy7 antibody respectively (average of 4 independent experiments ± SEM). (c) Detection 
of FcεRI-II via flow cytometry on monocytes, M0, M1 and M2 ex vivo differentiated macrophages. Data represent 
the percentage of positive cells to anti-human FcεRI-PE, anti-human CD23-BV421 antibodies (average of 4 
independent experiments ± SEM). Statistical analysis obtained performing One-way ANOVA coupled with 
Tukey’s post-test (*** p-value<0.0005, ** p-value<0.005, * p-value<0.05). 
 
 
Figure 2. Cross-linking of cell-bound IgE regulates macrophage secretion of soluble mediators  
(a) Schematic representation of the cross-linking of IgE antibodies on macrophages. (b-e) Differentiated 
macrophages were incubated with SF-25 IgE or NIP IgE antibody alone for 30 minutes at 37°C or followed by a 
second 30 minutes incubation with anti-human IgE antibody in order to cross-link the cell-bound IgEs. (b) 
Quantification of Pro-inflammatory cytokines TNFα, IFNγ, IL-12, IL-1β, (c) Anti-inflammatory cytokines IL-4, 
IL-6, IL-10, IL-13, (d) Interferon Gamma-induced chemokines MIG (CXCL9) and I-TAC (CXCL11) and (e) 
Macrophage chemoattractant chemokines MCP-1 (CCL2) and RANTES (CCL5) levels were analyzed via 
Luminex magnetic assay. Values are expressed as pg/mL (average of two independent experiments ± SEM). 
 
Figure 3. Kinase phosphorylation is differentially altered between M1 and M2 macrophages upon IgE 
cross-linking 
(a) Images from Proteome Profiler Human Phospho-Kinase Array (decrease in phosphorylation marked in red; 
increase in phosphorylation marked in green). Each kinase is spotted in duplicate. (b) Schematic representation 
of the percentage of increase and decrease in phosphorylation levels in M1 and M2 macrophages upon IgE cross-
linking. (c) Pixel densitometry analysis was expressed as fold change comparing the sample subjected to IgE 
cross-linking to the corresponding non-treated sample.  
 
Figure 4. Human M1 and M2 macrophages display differential signaling cascade upon IgE engagement 
(a) FcERI pathway network generated via KEGG database. Highlighted in blue are kinases analysed via Human 
Phospho-Kinase Antibody Array. (b) List of implicated pathways upon IgE cross-linking, represented as the 
average fold change of implication between M1 and M2 macrophages. Data generated via Reactome.  
 
Figure 5. Effects of IgE cross-linking on macrophage gene expression and correlation of LYN and TIM-3 
expression of tumour patient prognosis 
(a) Differentiated M0, M1 and M2 macrophages were treated with: SF-25 IgE alone, anti-human IgE or both. The 
effects of IgE cross-linking on gene expression of LYN and TIM-3 were detected by performing RT-PCR on 
mRNA content of treated and lysed cells. Values are expressed as fold change compared to the untreated cell 
sample of one single preliminary experiment. (b) Association between mRNA expression of crucial elements of 
Fc$RI pathway LYN and TIM-3 and 5-year survival of patients in cohorts of gastric, lung and ovarian cancer 
were analysed. Graphs show Kaplan-Meyer survival curves upon discrimination between high and low expression 
levels of genes of interest Lyn and Tim-3. Threshold was set to the upper quartile of patients’ gene expression 
data: “high” expression represents the upper quartile, “low” expression encompasses the remaining data of the 
set. 
 
Figure 6. IgE antibodies activate ex vivo monocyte-derived macrophages towards A-2058 melanoma cells 
The tumour cell killing assay was performed in order to investigate a) the ability of IgE antibodies to activate ex 
vivo derived macrophages and b) whether the different phenotypes could reflect into different anti-tumour activity. 
(a) Representative flow cytometry plots depicting the gating strategy applied for detection of cytotoxic and 
phagocytic activity of macrophages. The black gate highlights the double positive cells, indicating phagocytic 
activity (CFSE+ tumour cells internalized by macrophages). The purple gate emphasizes the loss in the total 
number of tumour cells when incubated with SF-25 IgE antibody. (b) Tumour cell killing was investigated in PBS 
control conditions, with 5 µg/ml of SF-25 IgE, SF-25 IgG1 and negative (non-specific) (NIP IgE or IgG1) antibody 
controls. Values are represented as percentage of tumour killing (average of 2 independent experiments ± SEM; 
each condition was tested in triplicate). Statistical analysis obtained performing One-way ANOVA coupled with 
Bonferroni’s post-test; ** p-value=0.0012, * p-value=0.01 (M1) and 0.03 (M2) (* p-value= 0.01) *=p-value<0.05, 
**=p-value<0.01 
 
Figure 7. IgE antibody-mediated re-programing of human macrophages 
Schematic picture illustrating the suggested model of repolarization of human macrophages via engagement and 
activation by IgE antibodies: quiescent M0 macrophages and anti-inflammatory M2 macrophages are skewed 
towards a new polarization phenotype, displaying both pro- and anti-inflammatory features.  
 
Table 1. Summary of IgE antibody-mediated effects on human macrophage phenotypes 
List of soluble mediators released, gene expression and kinase phosphorylation modifications engendered on 
human macrophage subsets upon IgE crosslinking. Quiescent M0 and M2 macrophages cross-linked with IgE 
antibodies acquire typical M1 marker features and are skewed towards a new polarization status (yellow 
macrophage). IgE cross-linked on the surface of M1 macrophages retains a pro-inflammatory, anti-tumour 
polarization status. The five most perturbed kinases amongst 43 analysed are reported in this table. The red arrow 
indicates increase/decrease of release, expression or phosphorylation level compared to baseline conditions.  
Supplemental Material 
Supplementary Figure 1 Gating strategy for monocyte purity evaluation 
(a) Representative flow cytometry plots depict cell populations in sample fractions. (b) Level of monocyte purity 
in the isolated samples (n=4) via CD14 and CD16 staining. Values are represented as percentage of positive cells 
(average of n=3 independent experiments ± SEM). 
 
Supplementary Figure 2. Surface levels of endogenous IgE on differentiated macrophages 
Representative flow cytometry plots of two independent experiments for quantification of endogenous IgE bound 
to differentiated macrophages, treated with anti-human IgE-FITC only or SF-25 IgE and anti-human IgE-FITC 
combined. FITC-positive cells are gated and relative percentage to whole cell sample is depicted.  
 
Supplementary Figure 3. Cross-linking of cell-bound IgE regulates surface marker levels of macrophages 
Differentiated macrophages (n=3) were incubated with SF-25 IgE or NIP IgE antibody alone or in combination 
with anti-human IgE antibody. Monocyte, M1 and M2 typical surface marker levels were analyzed before and 
after treatment by staining the cells with fluorescently labelled antibodies targeting CD14, CD16, Fc%RI, Fc%RII 
(CD23), CD80, CD86, CD163 and CD206. Values are expressed as fold change compared to the non-treated 
sample ± SEM, based on a number of 3 independent experiments.  
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Summary of IgE antibody-mediated effects on human macrophage phenotypes 
 
 
Table 1. List of soluble mediators released, gene expression and kinase phosphorylation modifications engendered 
on human macrophage subsets upon IgE crosslinking. Quiescent M0 and M2 macrophages cross-linked with IgE 
antibodies acquire typical M1 marker features and are skewed towards a new polarization status (yellow 
macrophage). IgE cross-linking on M1 macrophages retains a pro-inflammatory, anti-tumour polarization status. 
The five most perturbed kinases amongst 43 analysed were reported in this table. The red arrow indicates 
increase/decrease of release, expression or phosphorylation level compared to baseline conditions. 
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